X4 Pharmaceuticals

XFOR

Market cap $383M

4.21 USD

+0.10

2.43%

At close Updated Apr 27, 4:00 PM EDT

Pre-market

After hours

4.18

-0.03

0.71%

1 day

2.43%

5 days

-0.47%

1 month

4.21%

3 months

13.78%

6 months

12.57%

Year to date

8.23%

1 year

-21.16%

5 years

-98.35%

10 years

-99.83%

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 45

Healthcare Biotechnology